{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:20:21Z","timestamp":1790893221527,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.euroneuro.2006.04.004","type":"journal-article","created":{"date-parts":[[2006,5,27]],"date-time":"2006-05-27T11:15:13Z","timestamp":1148728513000},"page":"S119-S127","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S2","title":["Therapeutic options: Addressing the current dilemma"],"prefix":"10.1016","volume":"16","author":[{"given":"Timothy","family":"Dinan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2006.04.004_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0193-953X(05)70206-9","article-title":"Cognitive theories of generalized anxiety disorder","volume":"24","author":"Aikins","year":"2001","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib2","first-page":"165","article-title":"Changes on the Temperament and Character Inventory after paroxetine treatment in volunteers with generalized anxiety disorder","volume":"34","author":"Allgulander","year":"1998","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib3","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1176\/appi.ajp.161.9.1642","article-title":"Efficacy of sertraline in a 12-week trial for generalized anxiety disorder","volume":"161","author":"Allgulander","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1192\/bjp.179.1.15","article-title":"Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study","volume":"179","author":"Allgulander","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib5","series-title":"Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report of the American Psychiatric Association","first-page":"25","article-title":"Risk factors for clinically important physiological benzodiazepine dependence","author":"American Psychiatric Association Task Force on Benzodiazepine Dependency","year":"1990"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib6","series-title":"Diagnostic and Statistical Manual of Mental Disorders","first-page":"232","article-title":"Diagnostic criteria for generalized anxiety disorder","author":"American Psychiatric Association","year":"1980"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1037\/0022-006X.61.4.611","article-title":"Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder","volume":"61","author":"Borkovec","year":"1993","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0278-5846(95)00102-2","article-title":"Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam","volume":"19","author":"Bourin","year":"1995","journal-title":"Prog. Neuro-psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib9","doi-asserted-by":"crossref","unstructured":"Brawman-Mintzer, O., Knapp, R., Rynn, M., Carter,R., Rickels, K., 2006. Sertraline treatment for generalized anxiety disorder: results of a double-blind, placebo-controlled study. J. Clin. Psychiatry, in press.","DOI":"10.4088\/JCP.v67n0603"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4088\/JCP.v60n0805","article-title":"Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder","volume":"60","author":"Davidson","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/da.10146","article-title":"Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study","volume":"19","author":"Davidson","year":"2004","journal-title":"Depress. Anxiety"},{"issue":"Suppl. 4","key":"10.1016\/j.euroneuro.2006.04.004_bib12","first-page":"19","article-title":"The pharmacologic profile of mirtazapine","volume":"57","author":"de Boer","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4088\/JCP.v61n0203","article-title":"Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder","volume":"61","author":"DeMartinis","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/BF02244440","article-title":"Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder","volume":"105","author":"Enkelmann","year":"1991","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib15","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1176\/ajp.154.12.1760","article-title":"Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine","volume":"154","author":"Fava","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000118565","article-title":"Analysis of individual symptoms in generalized anxiety\u2014a pooled, multistudy, double-blind evaluation of buspirone","volume":"21","author":"Feighner","year":"1989","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib17","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1017\/S0033291799001336","article-title":"Recovery rates in generalized anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-T across outcome studies since 1990","volume":"29","author":"Fisher","year":"1999","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib18","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1001\/jama.283.23.3082","article-title":"Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial","volume":"283","author":"Gelenberg","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib19","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4088\/JCP.v60n0705","article-title":"Mirtazapine in major depression with comorbid generalized anxiety disorder","volume":"60","author":"Goodnick","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib20","first-page":"671","article-title":"An open trial of nefazodone in adult patients with generalized anxiety disorder","volume":"32","author":"Hedges","year":"1996","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib21","first-page":"293","article-title":"Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms","volume":"49","author":"Hoehn-Saric","year":"1988","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2165\/00003495-199549020-00010","article-title":"Venlafaxine. A review of its pharmacology and therapeutic potential in depression","volume":"49","author":"Holliday","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s002130050578","article-title":"Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients","volume":"136","author":"Laakmann","year":"1998","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1192\/S0007125000293513","article-title":"Interaction of pharmacological and psychological treatments of anxiety","author":"Lader","year":"1998","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib25","first-page":"481","article-title":"Beta-blocking drugs and anxiety. A proven therapeutic value","volume":"17","author":"Laverdure","year":"1991","journal-title":"Encephale"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00002018-199614040-00002","article-title":"Monoamine oxidase inhibitors. An update on drug interactions","volume":"14","author":"Livingston","year":"1996","journal-title":"Drug Safety"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1037\/0022-006X.64.4.660","article-title":"Recent developments in the psychopharmacology of anxiety disorders","volume":"64","author":"Lydiard","year":"1996","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4088\/JCP.v61n0204","article-title":"Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group","volume":"61","author":"Mehtonen","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib29","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/archpsyc.1983.01790090061009","article-title":"The effect of buspirone on prolactin and growth hormone secretion in man","volume":"40","author":"Meltzer","year":"1983","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib30","unstructured":"National Institute for Clinical Excellence (NICE), 2004. Anxiety. Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. (CG22 Anxiety\u2014Nice guideline). Available from: http:\/\/www.nice.org.uk\/page.aspx?o=cg022niceguidelines. Accessed May 2006."},{"issue":"Suppl. 4","key":"10.1016\/j.euroneuro.2006.04.004_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1017\/S1092852900025475","article-title":"Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis","volume":"9","author":"Nemeroff","year":"2004","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0447.1997.tb05956.x","article-title":"Mirtazapine: pharmacology in relation to adverse effects","volume":"391","author":"Nutt","year":"1997","journal-title":"Acta Psychiatr. Scand. Suppl"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1192\/bjp.179.5.390","article-title":"New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder","volume":"179","author":"Nutt","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib33","first-page":"S105","article-title":"Generalized Anxiety Disorder: A Comorbid Disease","volume":"16","author":"Nutt","year":"2006","journal-title":"Eur. Neuropsychopharmacol. Suppl."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib35","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","article-title":"Pregabalin in generalized anxiety disorder: a placebo-controlled trial","volume":"160","author":"Pande","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib36","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1177\/070674378903400804","article-title":"Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo","volume":"34","author":"Pecknold","year":"1989","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib37","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4088\/JCP.v62n0508","article-title":"Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial","volume":"62","author":"Pollack","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib38","first-page":"289","article-title":"Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care","volume":"40","author":"Power","year":"1990","journal-title":"Br. J. Gen. Pract."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib39","unstructured":"Preskorn, S.H., 1999. Outpatient Management of Depression: A Guide for the Primary-Care Practitioner. Evaluating the Various Antidepressants. Available at: http:\/\/www.preskorn.com\/books\/omd_s8.html. Accessed May 2006."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib40","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0025-6196(12)61375-5","article-title":"Pharmacology of antidepressants\u2014characteristics of the ideal drug","volume":"69","author":"Richelson","year":"1994","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/S0007125000293525","article-title":"The spectrum of generalised anxiety in clinical practice: the role of short-term, intermittent treatment","author":"Rickels","year":"1998","journal-title":"Br. J. Psychiatry"},{"issue":"Suppl. 14","key":"10.1016\/j.euroneuro.2006.04.004_bib47","first-page":"9","article-title":"Pharmacotherapy of generalized anxiety disorder","volume":"63","author":"Rickels","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib45","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1176\/ajp.145.3.312","article-title":"Clorazepate and lorazepam: clinical improvement and rebound anxiety","volume":"145","author":"Rickels","year":"1988","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib49","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/archpsyc.1988.01800290060008","article-title":"Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone","volume":"45","author":"Rickels","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib44","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archpsyc.1993.01820230054005","article-title":"Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam","volume":"50","author":"Rickels","year":"1993","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib50","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00004714-199708000-00006","article-title":"Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial","volume":"17","author":"Rickels","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.euroneuro.2006.04.004_bib43","doi-asserted-by":"crossref","first-page":"12S","DOI":"10.1097\/00004714-199912002-00003","article-title":"Pharmacologic strategies for discontinuing benzodiazepine treatment","volume":"19","author":"Rickels","year":"1999","journal-title":"J. Clin. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00004714-200002000-00004","article-title":"A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder","volume":"20","author":"Rickels","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib42","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1176\/appi.ajp.157.12.1973","article-title":"Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy","volume":"157","author":"Rickels","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib46","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1176\/appi.ajp.157.6.968","article-title":"Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder","volume":"157","author":"Rickels","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib51","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1176\/appi.ajp.160.4.749","article-title":"Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study","volume":"160","author":"Rickels","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib52","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1600-0447.1997.tb09660.x","article-title":"Paroxetine efficacy in the treatment of generalized anxiety disorder","volume":"95","author":"Rocca","year":"1997","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib53","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1176\/ajp.152.8.1161","article-title":"Clinical aspects of chronic use of alprazolam and lorazepam","volume":"152","author":"Romach","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib54","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/10673229309017080","article-title":"Neurobiologic basis of anxiety and its treatment","volume":"1","author":"Salzman","year":"1993","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib55","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199305133281907","article-title":"Use of benzodiazepines in anxiety disorders","volume":"328","author":"Shader","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib61","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.4088\/JCP.v66n1015","article-title":"Randomized trial of Sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms","volume":"66","author":"Sir","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib56","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4088\/JCP.v64n0305","article-title":"Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder","volume":"64","author":"Stocchi","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib57","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1096\/fasebj.2.9.2836252","article-title":"Buspirone, a new approach to the treatment of anxiety","volume":"2","author":"Taylor","year":"1988","journal-title":"FASEB J."},{"key":"10.1016\/j.euroneuro.2006.04.004_bib58","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1749-6632.1990.tb16909.x","article-title":"Serotonin agents in anxiety","volume":"600","author":"Taylor","year":"1990","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"Suppl. 6","key":"10.1016\/j.euroneuro.2006.04.004_bib59","first-page":"3","article-title":"Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug","volume":"56","author":"Taylor","year":"1995","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib60","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4088\/JCP.v59n1002","article-title":"Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients","volume":"59","author":"Thase","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1192\/S0007125000293471","article-title":"Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO study on Psychological Problems in General Health Care","author":"Weiller","year":"1998","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib63","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/archpsyc.1994.03950050015002","article-title":"DSM-III-R generalized anxiety disorder in the National Comorbidity Survey","volume":"51","author":"Wittchen","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.04.004_bib64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0447.2000.tb10947.x","article-title":"Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors","volume":"Suppl. 403","author":"Zohar","year":"2000","journal-title":"Acta Psychiatr. Scand."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X06000721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X06000721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T01:29:28Z","timestamp":1555637368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X06000721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":64,"alternative-id":["S0924977X06000721"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2006.04.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}